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Percutaneous transluminal coronary angioplasty 
(PTCA) is an accepted treatment for providing relief 
of angina pectoris in patients with single-and multi- 
vessel disease. Increased experience and advances in 
technology have resulted in a high primary success 
rate (90 % to 95 % ) and a lower complication rate (4 % 
to 5 % ). Despite the therapeutic success of coronary 
angioplasty, the exact mechanisms of dilatation re- 
main speculative and involve multiple processes in- 
cluding stretching of the vessel at the site of the di- 
latation and disruption and fissuring of the plaque.’ 
Angiographic renarrowing at the site of PTCA, fre- 
quently accompanied by recurrence of symptoms of 
angina, is a common phenomenon (30 % ) and has a 
negative bearing on the long-term results of PTCA. 
This usually occurs within the first 6 months after 
PTCA.“, ” Although many of the risk factors for re- 
stenosis have been identified (Table 1),4-25 most of 
these are difficult to influence. Until now we have not 
found a technical or pharmacologic cure, and we are 
unable to predict which patients or vessel segments 
will have restenosis. The reason why a clinically sig- 
nificant restenosis occurs in only a minority of the 
dilated vessels (30%) remains an enigma. Although 
the typical restenotic lesion differs from the usual 
atherosclerotic plaque in architecture and lipid 
content, both contain smooth muscle cells and fi- 
brous tissue,P6. 27 and it is even likely that the 
factors responsible for restenosis are similar to 
those that effect de novo atherosclerosis. In some 
cases of “restenosis” it is conceivable that it is 
caused by progression of the preexisting athero- 
sclerotic plaque. 
An important step in the restenosis process is ac- 
tivation of the hemostatic system with platelet adhe- 
sion, platelet aggregation, and fibrin formation. This 
is followed by smooth muscle cell proliferation, which 
is mediated by growth factors produced by cellular 
constituents in the blood and damaged vessel 
wa11.2”~2g Each of these steps could be sites of inter- 
vention that might halt the restenosis process. The 
drugs that could reduce or prevent restenosis in the 
animal model are listed in Table II. Some of these 
have been investigated in prospective randomized 
angioplasty trials and although efficacy has not been 
demonstrated, they continue to be used and pre- 
scribed in daily routine. In this review we will concen- 
trate on the drugs (Fig. 1) that have been tested to pre- 
vent restenosis in the animal model (Table III) and in 
postangioplasty patients (Table IV). 
Animal models are of limited value in restenosis 
research because it is impossible to create arterial 
stenoses in animals (e.g., pigs, rabbits, or dogs) that 
resemble human coronary artery disease (Table V). 
Most models use an inflated balloon to “injure” the 
intimal and medial layers of the vessel wall, although 
infused air has also been used. Some investigators 
have performed experiments in iliac or carotid arte- 
ries rather than in coronary arteries; others have fed 
the animals an atherogenic diet for brief periods of 
time to induce an “atherosclerotic lesion.” Several 
studies in animals have examined the degree of 
platelet deposition after arterial injury to test the 
hypothesis that platelet aggregation and platelet-de- 
rived substances are responsible for the restenosis 
process.2g-“’ Other studies use angiographic or histo- 
logic findings in damaged arteries to assess resteno- 
sis (Table IV). Recently a model of human restenosis 
171 
172 Hermans et al. 
July 1991 
American Heart Journal 
Table I. Variables associated with higher restenosis rates in patients with follow-up angiography 
Reference Year No. of patients Clinical 
Holmes et al.* 1984 557 Male sex 
Canadian class III-IV 
No previous MI 
- 
Cowley et al5 1985 557 
Leimgruber et al.6 1986 998 
Kaltenbach et a1.7 
Levine et a1.s 
Bertrand et al3 
Uebis et allo 
1985 333 
Angina onset (2 mo 
Diabetes mellitus 
Male sex 
Old age 
Unstable angina 
Angina onset (2 mo 
Medication ? 
1985 100 
1986 229 
1986 100 
David et al.” 1984 191 Variant angina 
Hollman et all2 1986 536 Diabetes mellitus 
Scholl et a1.i3 1981 45 
Margolis et al.‘* 1984 216 
Marantz et a1.15 1984 73 
Variant angina 
Insulin-dependent diabetes mellitus 
Mata et al.‘” 1985 63 
Probst et al.” 1985 94 
Serruys et al.@ 1985 28 
Roubin et all9 1986 411 
Shaw et a1.20 1986 97 High cholesterol 
Current smoker 
Clark et a1.21 
Powelson et a1.22 
Urban et a1.23 
Bertrand et a12* 
1986 124 
1986 50 
1987 91 
1989 437 
Ellis et a1.25 1989 308 
BIP, balloon inflation pressure; CABG, coronary artery bypass graft; DS, diameter stenosis; Ml, myocardial infarction; TSG, transstenotic gradient; CWP, 
coronary wedge pressure. 
*In patients with totally rzcluded vessel. 
tEarly restenosis (<2 days). 
was developed in the domestic crossbred swine fed a ination of lesions showed a marked proliferation of 
standard nonatherogenic diet.32 Metallic foreign medial smooth muscle cells. This may be a useful an- 
bodies were implanted percutaneously in porcine imal model to test drugs used for treatment of re- 
coronary arteries with oversized PTCA balloons stenosis, since it more closely resembles the response 
inflated to high pressure. Results of histologic exam- in human restenosis. 
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Hemodynnmic or 
procedure-related Lesion-related 
Pre-PTCA TSG 
~40 mm Hg 
Post,-PTCA TN; 
~20 mm Hg 
Post-PTCA TSG 
15 mm Hg 
Inflation pressure 
<8 atm 
Post-PTCA TSG 
>18 mm Hg 
Maximum balloon 
pressure >7 atm 
Balloon artery ratio 
50.9 
Pre-PTCA DS > 70% 
PTCA on CABG 
LAD>RCA>LCX 
Post-PTCA DS >30? 
Absence of dissection 
Second PTCA 
PTCA on CABG 
Post-PTCA DS >30O’r 
Relative change <55% 
“Dynamic” coronary stenosis 
Length of pre-PTCA stenosis 
>2 mm 
Pre-PTCA DS >90% 
Post-PTCA DS >50!‘,. 
Concentric stenosis 
Multivessel PTCA 
Pre-PTCA DS 290% 
Post-PTCA DS >40A 
Absence of intimal tear 
Eccentric or calcified lesion 
Irregular lesion pre-PTCA 
Large change in DS at PTCA 
LAD or LCX >RCA 
Calcified stenosis 
Post PTCA DS >40C; 
Collaterals pre-PTCA 
Occlusion pressure 
>45 mm Hg 
PTCA for total occlusion 
Multilesion PTCA in one vessel 
More inflations* 
Higher BIP* 
CWP z-30 mm Hg 
Presence of intimal disruptiont 
Presence of ergonovine-induced 
spasm before and 
after PTCA 
Stenosis at bend point of 
coronary artery 
ANTICOAGULANTS AND ANTIPLATELET AGENTS 
Platelets play an important role in the develop- 
ment of reatenosis after PTCA.33 Intact endothelium 
prevents platelet aggregation; however, after super- 
ficial injury a thin layer of thrombocytes attach 
themselves to the endothelium (platelet adhesion). 
If, however, there is deeper damage to the vessel wall, 
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blood is exposed to collagen and other substances of 
the subintima, which is a potent stimulus for plate- 
let aggregation that is mediated by the release of ad- 
enosine diphosphate, serotonin, thromboxane AZ, fi- 
brinogen, fibronectin, and von Willebrand factor. 
These substances activate neighboring platelets via 
different metabolic pathways (thromboxane AZ, ad- 
enosine diphosphate, and a platelet-activating fac- 
tor) and promote thrombosis. In addition, the release 
of several growth factors, including platelet-derived 
growth factor, epidermal growth factor, and trans- 
forming growth factor beta from thrombocytes, 
smooth muscle cells, endothelium, and macrophages, 
stimulates smooth muscle cells and fibroblasts to 
proliferate and migrate from the medial layer into the 
intima of the vessel wall. In some patients this 
response is excessive and is associated with formation 
of abundant amounts of connective tissue. This 
results in hyperplasia of the intima with a reduction 
in luminal diameter. 
To prevent plateletdeposition (whichoccurs within 
minutes of the procedure) and the associated release 
of smooth muscle cell mitogenic factors, antiplatelet 
therapy appears to be a logical approach. Experi- 
mental studies have demonstrated that the use of 
antiplatelet agents can decrease the extent of plate- 
let deposition and acute thrombosis after angioplas- 
ty, with some agents reducing the rate of restenosis 
in the Pig model (dipyridamole [2.5 
mg/day] + acetylsalicylic acid [20 mg/kg/dayJ, low- 
dose acetylsalicylic acid [ 1 mglkgfday f , anagrelide, 
intravenous nitroglycerin, and intravenous 
ibuprofen).2g,“4 Because only one of three pathways 
of platelet activation is blocked by current platelet- 
inhibitor therapy, it is not surprising that these 
agents are insufficient to prevent restenosis when 
tested in patients (Fig. 1). 
Heparin. For many years heparin has been an inte- 
gral aspect of the PTCA procedure since it binds 
reversibly with antithrombin, which results in in- 
creased activity of antithrombin. The antithrombin- 
heparin complex then binds with factor Xa and fac- 
tor IIa resulting in an anticoagulant effect (believed 
to be the result of its IIa effect) and an antithrom- 
botic effect (through its anti-Xa activity). Early 
discontinuation of heparin after angioplasty is asso- 
ciated with acute occlusion of the dilated arterial 
segment, suggesting that anticoagulation is impor- 
tant in the early stages after PTCA. However, the 
optimum duration of heparin thera.py is still un- 
known. 
A prospective trial conducted by the M-HEART 
study group35 with 209 patients showed an inverse 
relationship between the duration of heparin therapy 
and the incidence of restenosis. This was not con- 
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Fig. 1. Simplified schematic presentation of how the different drugs act on the different processes involved 
in the restenosis process (Modified from Fuster V et al. Prog Cardiovasc Dis 1987;22:325-46.) ASA, Ace- 
tylsalicylic acid; NSAID, nonsteroidal antiinflammatory drugs; TxA2, thromboxane A2; 7E3, antiplatelet 
glycoprotein receptor 2B/3A; ADP, adenosine diphosphate; LMWH, low molecular weight heparin; CAMP, 
cyclic adenosine monophosphate; IGF, insulin-like growth factor; FGF, fibroblastic growth factor; SMC, 
smooth muscle cell. - - 
Table II. Mechanisms to prevent restenosis 
Thrombosis 
Heparin, hirudin, coumadin, acetylsalicylic acid, dipyrida- 
mole, sulfinpyrazone, thromboxane A2 synthetase inhibi- 
tor, thromboxane AZ receptor blocker, ticlopidine, prosta- 
cyclin, ciprostene, 7E3, fish oil, NSAID, ridogrel 
Cell proliferation 
Low-molecular-weight heparin, platelet-derived growth 
factor antagonist (trapidil), angiotensin-converting en- 
zyme inhibitor (cilazapril), colchicine, cytostatic agents, 
serotonin antagonist (ketanserin), angiopeptin 
Inhibitor of inflammation 
Corticosteroids, nonsteroidal antiinflammatory drugs 
Coronary vasospasm 
Nifedipine, diltiazem 
Lipid regulators 
Fish oil, lovastatin 
firmed in a randomized trial with 416 patients (469 
stenoses) in Atlanta. 36 No differences in acute closure 
and restenosis were found in patients (all were with- 
out dissection; intimal flap inside or outside the lu- 
men) randomly assigned to placebo or 18 to 24 hours 
of heparin after PTCA (all patients received acetyl- 
salicylic acid for 6 months). Restenosis was defined as 
a narrowing of more than 50% of the vessel at the 
time of follow-up angiography, which was performed 
in only 58.4% of the patients treated with heparin 
and 64.5% of the patients given placebo. More 
bleeding complications were seen in the group of pa- 
tients who were treated with heparin (8.2 % vs 3.8% ). 
Acute total closure was seen more frequently in the 
group given placebo (2.4% ) than in the group treated 
with heparin (1.8%), and the restenosis rate was 
41.2% with heparin and 36.7% with placebo. 
Because low-molecular-weight heparin affects 
platelet aggregation and platelet-dependent throm- 
bin generation to a lesser extent than “regular” 
heparin, it has fewer side effects and yet both forms 
are known to inhibit the proliferation of vascular 
smooth muscle cells (dose dependent) and thrombo- 
sis after endothelial injury in the rat.37, 38 The mech- 
anism of this inhibition is not clear.3g Recently low- 
molecular-weight heparin has been used after trans- 
luminal angioplasty of rabbit iliac arteries.40 Two 
groups were studied: the first group (n = 9) received 
low-molecular-weight heparin (10 mg/kg/day subcu- 
taneously) immediately before transluminal angio- 
plasty until follow-up angiography 1 month later, 
whereas the second group (n = 12) received a pla- 
cebo. After 4 weeks all rabbits in the placebo group 
and three of nine rabbits in the group treated with 
low-molecular-weight heparin had a loss of more 
than 50% of the gain in diameter after transluminal 
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angioplasty. Histologic findings showed reduced in- 
timal hyperplasia and no formation of thrombus in 
the group treated with low-molecular-weight hep- 
arin. A multicenter double-blind control trial with 
low-molecular-weight heparin (Enoxaparin) is cur- 
rently underway in the United States. Patients with- 
out prior PTCA or recent myocardial infarction 
(within 5 days) are randomly assigned to placebo or 
low-molecular-weight heparin (30 mg subcutane- 
ously) for 1 month, and all patients will undergo re- 
peat angiography at 6 months. This will provide im- 
portant information about whether long-term ad- 
ministration of low-molecular-weight heparin can 
decrease the rate of restenosis. 
Hirudin. Newer anticoagulant drugs such as recom- 
binant hirudin are becoming available. Hirudin 
prevents fibrinogen clotting, thrombin-catalyzed ac- 
tivation of factors V, VIII, and XIII, and thrombin- 
induced platelet activation. Hirudin has been shown 
to be more effective in preventing thrombosis than 
heparin (by quantifying the deposition of platelets 
and fibrinogen by means of the method of Dewanje 
in a swine model). This latter effect is probably due 
to the fact that hirudin is a more potent and specific 
thrombin antagonist. 41 Trials designed to test the ef- 
ficacy of hirudin on early and late complications of 
PTCA are currently in the planning stages in Europe 
and the United States. 
Coumadin. Before Gruentzig began his work at 
Emory University in Atlanta in 1980, he had been 
administering coumadin (a vitamin K antagonist 
responsible for inhibiting thrombin formation) to his 
patients after balloon dilatation. In Atlanta his view 
was challenged since there was evidence that anti- 
platelet drugs were effective in preventing 
thrombosis in venous bypass grafts. To test this 
new therapeutic approach a trial was begun42 in 
which 248 patients were randomly assigned to either 
325 mg acetylsalicylic acid daily or coumadin at a 
dose that resulted in a prothrombin time that was 2 
to 2.5 times the normal value. In the group treated 
with acetylsalicylic acid (126 patients) restenosis 
was angiographically documented in 27% of the 
patients versus 36% of the patients treated with 
coumadin. A loss of >50% of the gain achieved at 
the time of PTCA or an increase in the stenosis of 
more than 30% (NHLBI IV) or development of pos- 
itive (for &hernia) exercise test results if no angio- 
gram was available were used as restenosis criteria. 
The results favored the acetylsalicylic acid strategy, 
but the difference was only significant for a subgroup 
of patients with a long history of chest pain (>6 
months). In patients with poor compliance resteno- 
sis rates were 32 % in the group treated with couma- 
din versus 20% in the group given acetylsalicylic 
acid. 
In London a more recent randomized tria14” with 
110 patients investigated the effect of a combination 
of coumadin and verapamil compared with verapamil 
alone. The incidence of restenosis was 25 % by lesion 
and 29% by patient in the group treated with 
coumadin and 33% and 37% in the control group 
(NHLBI IV criterion was used). Although the inci- 
dence of angiographic restenosis tended to be lower 
with coumadin, none of the differences were signifi- 
cant. A randomized trial to evaluate the efficacy of 
coumadin in the prevention of restenosis should be 
performed that would ensure adequate medication 
compliance with reliable and safe monitoring of pro- 
thrombin time. 
Acetylsalicylic acid. Acetylsalicylic acid is a “popu- 
lar drug” in restenosis prevention trials. In the ani- 
mal model it reduces platelet-thrombus deposition in 
a dose of 1 mg/kg/day when given in addition to 
heparin. Angiographic restenosis has also been shown 
to be reduced when acetylsalicylic acid is used in ad- 
dition to dipyridamole. 2g, 44 Acetylsalicylic acid has 
the ability to inhibit platelet thromboxane A2 syn- 
thetase and subsequent platelet activation by irre- 
versibly blocking the enzyme cyclooxygenase, which 
is responsible for the conversion of arachidonic acid 
to thromboxane AZ. At high doses acetylsalicylic acid 
may be less effective, since it inhibits the production 
of prostacyclin (which prevents platelet aggregation) 
by endothelial cells.45 However, it only partially in- 
hibits platelet aggregation induced by adenosine 
diphosphate, collagen, or thrombin. Consequently 
platelet-derived growth factor and other mitogens 
may still affect proliferation of smooth muscle celkP 
(Fig. 1). 
Acetylsalicylic acid has been studied in several 
prospective randomized trials. The first trial showed 
a reduction in the restenosis rate of 25%. when ace- 
tylsalicylic acid (325 mg) was compared with 
coumadin.4” Three trials compared different dosages 
of acetylsalicylic acid.46-48 In a trial in Homburg/ 
Saar, 203 patients were randomly assigned to either 
1500 mg/day or 320 mg/day. In a preliminary report 
25% of these patients had been restudied (6 months 
after PTCA). Results of follow-up angiography 
showed restenosis (>50% diameter stenosis) in 13 of 
44 (31% ) patients in the group treated with the lower 
dose compared with 9 of 42 patients (21% ) in the 
group given the higher dose.4” However, in a ran- 
domized trial in Atlanta with 495 patients, the effec- 
tiveness of two doses of acetylsalicylic acid (80 mg vs 
1500 mg daily started the day before PTCA) in the 
prevention of restenosis and acute complications af- 
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Table III. The effect of drug therapy in the animal model for prevention of restenosis 
Refrrencc Ear Model Drug 
-. 
Dosr, 
Clowes and Karnowsky3’ 19is 
Gordon et aJ.3g 1987 
Pow et aJ4’ 
Heras et al.” 
Faxon et a1.44 
1989 
1989 
1984 
Sanborn et a1.5” 1986 
I,iu et al.@ 
Currier et a1.65 
1990 
Rarath et aI.@ 1989 
J’owell et aJ6j 1989 
Miiller et al.@ 1990 
Foegh et al.” 1989 
Faxon et al.‘? 1984 
Cellman et al.*” 1990 
Rat 
A. carotis 
Rabbit aorta 
Rabbit 
A. iliaca 
Pig 
A. carotis 
Rabbit 
A. iliaca 
Rabbit 
A. iliaca 
Rabbit 
A. iliaca 
Rabbit 
A. iliaca 
Rabbit aorta 
Rats 
A. carotis 
Rats 
A. carotis 
Rabbit cardiac 
transplant 
Rabbit 
Rabbits 
A. femoralis 
Heparin 
Placebo 
LMWH 
Hydrocortisone 
LMWH + hydrocortisone 
Placebo 
LMWH 
Placebo 
Hirudin 
Heparin 
ASA + D 
Sulfinpyrazone 
Placebo 
TXA:! synthetase inhibitor 
Heparin 
ASA 
Trapidil 
Placebo 
Colchicine 
Colchicine 
Placebo 
Vincristine + actinomycin 
Placebo 
Cilazapril 
Placebo 
Captopril 
Hydralazine 
Verapamil 
Angiopeptin 
Placebo 
Nifedipine 
Placebo 
Lovastatin 
Placebo 
S-14 days 
2.5 mg/kg/day 
1 mg/kg/day 
10 mg/kg/day 
1 mglkglhr 
6 different doses 
32-25 mglday 
100 mg/day 
1 mglkglhr 
500 U/kg 
10 mg/kg 
60 mg/kg/day 
0.2 mg/kg 
0.02 mg/kg 
0.075 mg/kg 
+ 0.015 mg/kg 
10 mg/kg 
5 different durations 
100 mg/kg/day 
8 mg/kg/day 
100 mg/kg/day 
40 mg/day 
6 mg/kg/day 
ter PTCA was compared. 4’i Results of follow-up an- 
giography were available in only 166 patients (34% ). 
In the group treated with the low dose of acetylsal- 
icylic acid, 47 $5 of the patients had restenosis >50% 
diameter stenosis in one or more sites) compared with 
51% in the group treated with the high dose. There 
were no differences in success or acute complication 
rates. Thus restenosis was not influenced favorably 
by the use of a higher dose of acetylsalicylic acid. 
A smaller trial compared the effects of acetylsali- 
cylic acid in doses of 100 mg/day versus 1000 mg/day, 
started 1 day before PTCA until 6 months after 
PTCA.4” In addition, all patients received calcium 
channel blockers and long-acting nitrates. Restenosis 
(clinically significant stenosis requiring repeat PTCA 
or coronary artery bypass graft) occurred in 7 of the 
40 patients in the group treated with 100 mg acetyl- 
salicylic acid (18 % ) and in 8 of the 39 patients in the 
group treated with 1000mgacetylsalicylic acid (21% ). 
The investigators concluded that restenosis is not 
favorably influenced by the use of high-dose versus 
low-dose acetylsalicylic acid. Another tria14g designed 
to compare the effects of 100 mg acetylsalicylic acid 
with those of placebo was stopped prematurely after 
40 patients (single blind) were enrolled because of 
reports showing the benefit of acetylsalicylic acid 
(combined with dipyridamole) in preventing acute 
thrombosis in dilated vessels and the need for urgent 
bypass surgery. 6o Results of follow-up angiography at 
6 months (95 % of the patients) in this particular trial 
showed an incidence of restenosis (MO% diameter 
stenosis) that was two times higher in the group 
treated with acetylsalicylic acid (33 % ) compared 
with the group given a placebo (14 % ). Although the 
difference seems impressive, it was not statistically 
significant because of the small numbers. 
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_-._ - . - - I__ -  
Animals Total Follow-up Method Effect 
______ _..~--_-“_-_ - 
46 
1’: 
34 
36 
127 
20 
15 
30 
7 days 
2 wk 
4 wk 
4 wk 
30 min 
4 wk 
4 wk 
3 days 
14 days 
Not reported Histology 
6 wk Histology 
4 wk 
39 days 
Angiography 
Histology 
Arteriography 
Histology 
Histology 
Histology 
Angiography 
Histology 
Platelet deposition 
Angiography 
Histology 
Platelet deposition 
Arteriography 
Histology 
Arteriography (QCA) 
Histology 
Electron microscopy 
Histology 
Myointimal thickening less with hrparrn 
Ratio intimal/medial thickness in LMWH anti 
hydrocortisone separately and svnergisti!,aiiy lower 
than placebo 
1\ Luminal diameter (Post-PTCA)-(follow q~ 1 = I .I 
mm placebo and 0.3 mm LMWH (p < 0 001) 
Less platelet deposition with hirudin than heparin 
ASA + D and sulf’inpyrazone reduce restrt rx~is 
Less platelet accumulation with TSA-, svr!thrtase 
inhibitor 
Intimal thickness decreases with trapidil 
ALuminal diameter (Post-PTCA)-lf,,llow.. rp) = 0.6 mm 
= 0.8 mm 
= 1.1 mm 
Selective damage of proliferating smooth nuscle cells 
Intimal hypetplasia decreased with 7)“; !‘iven -6 -+ i .t 
days 
Captopril superior compared with others n reduction 
of intimal hyperplasia 
Intimal hyperplasia decreased by angiopeotln 
ALuminal diamet,er (Post-PTCA) (follow al)’ = 0.9 mm 
= 1.2 mm 
Intimal hyperplasia decreased with lovast,~tin 
In a well-designed trial at the Montreal Heart In- 
stitute and Toronto General Hospital,51 376 patients 
were randomly assigned to a combination of acetyl- 
salicylic acid (990 mg daily) and dipyridamole (225 
daily) or to placebo starting the day before PTCA 
until follow-up angiography 4 to 7 months later. More 
acute complications were seen in the placebo group, 
including 13 periprocedural myocardial infarctions 
in the placebo group versus three in the treated group 
(p < 0.05). However, no differences were observed in 
the restenosis rate (increase in diameter stenosis 
from <50 % after PTCA to >50 % at follow-up): 39 % 
(127 patients) in the placebo group compared with 
38 % (122 patients) in the treated group. All patients 
received heparin until 12 hours after the proce- 
dure (500 Ukr) and diltiazem until follow-up 
angiography. 
Chesebro et a1.52 randomly assigned 207 patients 
(297 stenoses) to either acetylsalicylic acid (975 mg/ 
day) and dipyridamole (225 mg/day) or to placebo 
from the day before PTCA until 6 months later. 
There was no difference in the restenosis rate defined 
in a linear model based on the minimum lumen 
diameter obtained by quantitative angiography. 
There were fewer acute complications (occlusion, 
myocardial infarction, repeat PTCA, coronary artery 
bypass graft <48 hours) in the group treated with 
acetylsalicylic acid and dipyridamole (11% vs 20 % in 
the placebo group) confirming the results of the 
Montreal/Toronto trial. It is clear from these data 
that although acetylsalicylic acid does not influence 
the incidence of restenosis, it definitely has a positive 
influence on acute complications during or immedi- 
ately after angioplasty. 
Dipyridamole. In a rabbit model t,reatment with 
acetylsalicylic acid and dipyridamole decreased 
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Table IV. The effect of drug therapy on restenosis in patients after successful coronary angioplasty 
Reference Year Drug 
Hirshfeld et a1.35 
Ellis et a1.36 
Thornton et a1.42 
Urban et a1.43 
Dyckmans et a1.46 
Mufson et a1.47 
Schanzenbacher et a1.48 
Finci et a1.4g 
Schwartz et aL5’ 
Chesebro et a1.52 
White et a1.53 
1987 
1989 
1984 
1988 
1988 
1988 
1988 
1988 
1988 
1989 
1987 
Yabe et a1.s5 1989 
Kitazume et aL5’j 1988 
Knudtson et a1.57 1990 
Raizner et a1.58 1988 
Klein et a1.64 1989 
Corcos et a1.73 1985 
Whitworth et a1.74 1986 
Slack et a1.7s 1987 
Reis et a1.76 1989 
Milner et a1.77 1989 
Dehmer et a1.78 1988 
Grigg et a1.79 1989 
Sahni et al.sr 1989 
Rose and Beauchamps 1987 
Stone et a1.s5 1989 
Pepine et a1.s6 1990 
Heparin Different durat,ion 209 
Heparin (18-24 hr) 
Dextrose 
Coumadin 
ASA 
Coumadin + Verapamil 
Verapamil 
ASA 
ASA 
ASA 
ASA 
ASA 
ASA 
ASA 
Placebo 
ASA +D 
Placebo 
ASA+D 
Placebo 
ASA+D 
Ticlopidine 
Placebo 
TXAl synthetase inhibitor 
Placebo 
ASA 
ASA + Ticlodipine 
ASA + Ticlodipine + Nicorandil 
Prostacyclin + ASA + D 
ASA + D 
Ciprostene 
Placebo 
<2.5 normal PTT 416 
2-2.5 normal PTT 
325 mglday 
>2.5 normal PTT 
Not reported 
1,500 mg/day 
320 mg/day 
1,500 mg/day 
80 mg/day 
1,000 mg/day 
100 mg/day 
100 mglday 
248 
110 
203 
453 
79 
40 
990-225 mg/day 249 
975-225 mglday 207 
650-225 mglday 
750 mgiday 
236 
600 mg/day 33 
300 mg/day 
+200 mg/day 
+30 mg/day 
5 ng/kg/min 
325 + 225 mg/day 
120 ng/kg/min 
maximum 48 hr 
280 
270 
311 
Ketanserin 
Not reported 
Diltiazem + ASA + D 
ASA + D 
Nifedipine + ASA 
ASA 
0.1 mg/min for 24 hr 
270 mglday 
650-225 mglday 
40 mg/day 
43 
92 
"41 
Fish oil 
Placebo 
Fish oil 
Placebo 
Fish oil 
Placebo 
Fish oil 
Placebo 
Fish oil 
Placebo 
Lovastatin 
Placebo 
Steroid 
Placebo 
Steroid for restenosis 
2.4 gm/day 162 
6.0 gm/day 186 
4.5 gmlday 194 
3.2 gmlday 82 
3.0 g/day 108 
‘O-40 mglday 157 
48 mglday 66 
125 mg methylprednisolone/day 
240 mg prednisone/week 
1.0 gm methylprednisolone 
102 
Steroid 
Placebo 
722 
Fup, follow-up (‘( of successful PTCA); DS. diameter of stenosis; PTT. prothrombin time: NS, not significant; ASA, acetylsalicylic acid; TXA?, thrombox- 
ane A?; I). dipyridamole. 
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Method Definition 
Not reported 
61’4 Angiography (3-9 mo) 
72’,, 
92’0 
77’, 
98’, 
40'1 
37’ 0 
100°C 
73'c 
1OO'cs 
72',, 
85 “i 
100 (‘,: 
loo”; 
8” f’( 
91’, 
85", 
30", 
loo”, 
23 I'< 
100 ('c 
100 c, 
94?, 
88', 
Angiography (4-E mo) 
Angiography (6-9 mo) 
Clinical 
Angiography (5 mo) 
Clinical 
Angiography (6 mo) 
(preliminary) 
Angiography (3-8 mo) 
Angiography (6 mo) 
Angiography (6 mo) 
Clinical 
Angiography (4-7 mo) 
Angiography (5 mo) 
(QCN 
Angiography (6 mo) 
Angiography (>3 mo) 
Angiography (6 mo) 
Angiography (6 mo) 
(caliper) 
Angiography (6 mo) 
Clinical 
(MI,re-PTCA,CABG,Death) 
Angiography (4-6 mo) 
Angiography 
Angiography (6 mo) 
Clinical 
Clinical (6 mo) 
Angiography (6 mo) 
Clinical 
Angiagraphy (6 mo) 
Clinical 
Angiography (6 mo) 
Angiography (3-5 mo) 
(caliper) 
Angiography (3 mo) 
Angiography (3 mo) 
Angiography (6 mo) 
Clinical 
Angiography (4-8 mo) 
(caliper) 
>5OC<t DS Fup 
(visual) 
>5OC;> DS Fup 
(visual) 
Loss >50”, of gain 
Stress test - -f + 
>50";. DS Fup 
>50"; DS Fup 
>5OC, DS Fup 
(visual) 
Clinical 
>50rc DS Fup (visual) 
>50';; DS Fup 
(QCA) 
Minimum diameter 
(Post-PTCA) (Fup) 
>7OC; DS Fup 
(visual) 
Loss >50c, of gain 
>50"; DS Fup 
>50% DS Fup or loss 
>50$ of gain 
>50% DS Fup 
(visual) 
Not reported 
(QCA) 
>7O";m DS Fup 
(visual) 
Loss >50 4, of gain 
>50c; DS Fup 
Stress test - -- + 
Stress test - - + 
>70'0 DS Fup 
Stress test - - + 
>50"; DS Fup 
Stress test - - + 
>50°; DS Fup 
(visual) 
Loss >50”; of gain 
>50”;, DS Fup 
>50$ DS Fup 
>5O'c DS Fup 
Stress test 
>50r; DS Fup 
Longer heparin. lw rrstenosia 
29’c 37’, Patient i = JVS 
25?, 33', Site I,= VF 
21c, 31’ ,, p = NS 
51“ 470, p= Nh 
38~; 39", p =NS 
A0.18 mm Placebo 13 = NS 
50.14 mm ASA t 1-t 
18 I’; p = NS 
29 ‘i 
2O'c 
22',;, 53?, p = NS 
38'S 
27?r 
16O1 p = 0.00: 
27';# 32”~ patient 11 = NS 
22?~ 29fi Site p = NS 
41r,a 53r; Angiography p = NS 
17’,, 34”; Clinical p < 0.001 
33 ',c 29 "; p = NS 
lii”( 22” I p=NS 
295 33', p = NS 
16"; 33"(# p < 0.05 Single vessel 
67”; 58’r p = NS Multivessel 
34"; 23c, ,o = NS 
18"~ 27', p = NS 
19$. 35';. p < 0.01 
16"; 36";# p < 0.0:; Site 
19?r, 46? p < O.Oi17 Patient 
34”; 33”(, p = NS Patient 
295 31 O, p = NS Lesion 
14(‘,, 47’, p < ().l?rll 
33"; 33', p = NP 
52% 54"<, p = NS Angiography 
58% 52rr p = NS Clinical 
40’~ 39’,# p = NS Lesion 
-- - 
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Table V. Animal models used to test drugs for prevention of restenosis 
Animal 
Rabbit 
Pig 
Dog 
Rat 
Vessel 
Artery 
Coronary 
Carotid 
Iliac 
Aorta 
Method 
1. Balloon denudation 
of endothelium 
2. Infused air 
1 or 2 with or without 
diet high in cholesterol 
3. Coil implantation 
4. Electrical stimulation 
Therapy End point 
Antiplatelet Platelet deposition 
Anticoagulant c5rCr or IllIn labeled) 
Antiproliferative Angiography 
Antiinflammatory Visual 
Calcium antagonist Quantitative 
Lipid lowering Histology 
platelet-thrombus deposition and restenosis after 
transluminal angioplasty by increasing platelet cyclic 
adenosine monophospate.44 However, in clinical 
trials51-53 no effect has been shown on the restenosis 
rate after angioplasty. 
Sulfinpyrazone. In contrast to acetylsalicylic acid, 
sulfinpyrazone is a competitve (reversible) inhibitor 
of platelet cyclooxygenase, but the exact mechanism 
of its antithrombotic activity is not well understood. 
Faxon et a1.44 showed a reduction in restenosis with 
the use of a rabbit model. There is no clinical 
evidence to date to support a role for sulfinpyrazone 
in the prevention of restenosis after coronary angio- 
plasty. 
Thromboxane A*synthetase inhibitor. Thromboxane 
AZ is a potent aggregating agent and vasoconstrictor. 
A specific inhibitor of thromboxane Aa can antago- 
nize these actions while at the same time leaving 
prostacycling production of the vascular endothe- 
lium unaffected. In rabbits it was shown that a selec- 
tive thromboxane synthetase inhibitor was more ef- 
fective than heparin or acetylsalicylic acid in inhib- 
iting platelet deposition after balloon angioplasty.54 
Another thromboxane AZ synthetase inhibitor was 
tested in a small number of patients to prevent res- 
tenosis after PTCA.55 It was given a minimum of 5 
days before PTCA and was continued until follow-up 
angiography (>3 months later). Restenosis was de- 
fined as a >50% loss of the initial gain in luminal di- 
ameter. The results showed that 4 of the 18 patients 
(22%) given thromboxane A2 synthetase inhibitor 
had restenosis versus 8 of the 15 patients (53 % ) in the 
placebo group. Besides inhibiting thromboxane A2 
synthetase, it is also possible to block the receptor of 
thromboxane on the platelet. Soon results will be 
available from a prospective European trial (Coro- 
nary Artery Restenosis Prevention On Repeated 
Thromboxane Antagonism) involving more than 700 
patients treated with either a thromboxane A2 re- 
ceptor blocker or placebo until follow-up angiogra- 
phy 6 months after PTCA. 
Ticlopidine. The mechanism of action of ticlopidine 
is not exactly known, but it is a potent platelet 
inhibitor. The optimum effect occurs 3 days after the 
first administration and lasts for at least several days. 
In a multicenter trial in the United States, patients 
were randomly assigned to ticlopidine (750 mg/day), 
to a combination of acetylsalicylic acid (650 mg/day) 
and dipyridamole (225 mg/day), or to placebo. Re- 
stenosis was defined as a diameter stenosis of 70 % or 
more at follow-up angiography (6 months). There 
was no difference in the restenosis rate; in the 65 pa- 
tients who received ticlopidine the restenosis rate 
was 29% compared with 18% in the 57 patients who 
received acetylsalicylic acid and dipyridamole. 
Among the 54 patients who received placebo, the 
restenosis rate was 20%. There was no difference in 
the acute complication rate.53 In Japan data collected 
retrospectively showed a lower restenosis rate when 
patients received a combination of ticlopidine (200 
mg/day), nicorandil (30 mg/day), and aspirin (300 
mg/day).56 
Prostacyclin or prostacyclin analogue. Prostacyclin 
is a potent naturally occurring platelet inhibitor and 
vasodilator. In a Canadian trial 270 patients were 
randomly assigned to placebo (136 patients) or pros- 
tacyclin (5 to 7 mg/min intravenously)( 134 patients) 
just before PTCA up to 48 hours after PTCA.5’ All 
patients received 325 mg acetylsalicylic acid and 225 
mg dipyridamole beginning before angioplasty until 
follow-up angiography 6 months later. Short-term 
administration of prostacyclin did not significantly 
lower the risk of restenosis: 27 % in the treated group 
compared with 32% in the placebo group. Resteno- 
sis was defined as 50% or more narrowing at follow- 
up angiography or >50% loss of the immediate gain 
after angioplasty. Acute vessel closure and ventricu- 
lar tachyarrhythmias were more common in the con- 
trol group than in the patients who received prosta- 
cyclin. 
Ciprostene. Ciprostene is a chemically stable ana- 
logue of prostacyclin. To study the effect of cipros- 
tene during PTCA, 311 patients were randomly 
assigned shortly before PTCA (40 ng/kg/min) to cip- 
rostene until 48 hours after PTCA (120 ngl’kglday) or 
to placebo. Acute closure occurred in three patients 
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in the placebo group and none in the ciprostene- 
treated group. Restenosis, defined as a diameter 
stenosis of 50% or more at the time of follow-up an- 
giography, was present in 52 of the 126 patients 
(41%) treated with ciprostene and in 65 of the 122 
patients (53 % ) given placebo. The clinical end points 
of this trial included death, myocardial infarction, 
repeat PTCA, or coronary artery bypass graft. In 30 
of the 149 patients (20%) treated with ciprostene, 
one of these clinical end points was observed com- 
pared with 55 of the 14’7 patients (33%) in the pla- 
cebo group. Although the clinical results were more 
favorable with ciprostene, there was no effect on the 
incidence of angiographic restenosis.58 
Prostaglandin El. Inasmuch as the deposition of 
platelets after angioplasty in porcine carotid arteries 
was reduced significantly after infusion with pros- 
taglandin El even more than with prostacyclin or 
dipyridamole, a study was attempted to determine 
the effect of intracoronary followed by intravenous 
prostaglandin Ei on restenosis. Eighty patients were 
randomly assigned to an infusion of 20 to 40 rig/kg/ 
min 12 hours before PTCA or placebo. Clinical 
follow-up showed abrupt occlusion in 3 of 40 patients 
in the placebo group compared with none in the 
prostaglandin El group. An additional repeat PTCA 
was necessary in 4 of 40 given placebo compared with 
none in the group treated with prostaglandin El. No 
angiographic study has assessed the effect of pros- 
taglandin El on restenosis.5g 
ANTIPROLIFERATIVE DRUGS 
Restenosis is characterized by migration and pro- 
liferation of smooth muscle cells in response to bal- 
loon injury. Although the mechanisms responsible 
for proliferation and migration of smooth muscle 
cells are not completely understood, it has been pos- 
tulated that they are controlled by the balance 
between growth factors and growth inhibitors re- 
leased from circulating blood cells, at local tissue 
sites, or both.28y 60, a1 Interference with growth factor- 
mediated cellular hyperplasia may be beneficial in 
inhibiting smooth muscle cell proliferation and 
thereby reduce restenosis (Fig. 1). 
Platelet-derived growth factor antagonist. Trapidil 
(triazolopyrimidine) has been shown to inhibit cellu- 
lar proliferation induced by platelet-derived growth 
factor in cell culture and intimal thickening in dam- 
aged carotid arteries. In a model of atherosclerosis 
rabbits were assigned to placebo (n = 8) or trapidil 
(60 mg/kg/day) (n = 9). The medication was started 
2 days before balloon dilatation of the external iliac 
artery and continued for 4 weeks. Follow-up angiog- 
raphy showed a greater luminal reduction in the 
control group than in the trapidil group (p < 0.001) 
compared with similar baseline values. Histologic 
findings showed significantly less intimal hyperplasia 
in the trapidil group compared with the placebo 
group.62 A clinical trial in angioplasty patients seems 
warranted. 
Serotonin antagonist. Serotonin, similar to platelet- 
derived growth factor, is released during platelet de- 
granulation at the time of vessel injury and appears 
to directly stimulate proliferation of smooth muscle 
cells in addition to potentiating the effects of plate- 
let-derived growth factor.6” Therefore administra- 
tion of a serotonin antagonist such as ketanserin may 
inhibit smooth muscle cell proliferation. Klein et a1.6’1 
studied the effects of ketanserin on the incidence of 
early and late restenosis. Ketanserin was given intra- 
venously (0.1 mg/min/24 hr) for 24 hours after PTCA 
to 21 patients. After 24 hours three patients in the 
placebo group had an occlusion compared with none 
in the control group. Follow-up angiography 4 to 6 
months later showed no difference in restenosis rates: 
29 % in the control group and 33 % in the ketanserin 
group. A large multicenter interventional trial (Post- 
Angioplasty Restenosis Ketanserin trial) with ket- 
anserin has recently been started and will elucidate 
the question of whether a longer administration (6 
months) has a beneficial effect on the incidence of 
restenosis. 
Colchicine. Colchicine inhibits the proliferation 
and migration of smooth muscle cells and the release 
of chemotactants by leukocytes.“” To study the effect 
of colchicine on restenosis, rabbits with atheroscle- 
rosis with >50% diameter stenosis underwent iliac 
transluminal angioplasty. Colchicine was started 2 
days before transluminal angioplasty (0.02 mg/day or 
0.2 mg/day) until follow-up angiography at 4 weeks. 
The high dose of colchicine significantly decreased 
the diameter stenosis at follow-up, although no effect 
was seen with the low dose. Clinical trials with colch- 
icine are currently in progress. However, it is likely 
that the efficacy of the drug will be limited by a high 
incidence of side effects (abdominal pain, vomiting 
diarrhea, and bone marrow depression). 
Cytostatic agents. After the disruptive action of 
balloon dilatation, a change in differentiation of 
smooth muscle cells (with a shift from the contractile 
to synthetic phenotype) is observed and accompa- 
nied by cell proliferation and extracellular matrix 
production, which is the basis for the restenosis pro- 
cess. Barath et a1.66 hypothesized t,hat cytostatic 
agents may prevent restenosis by selective injury to 
active and proliferating smooth muscle cells without 
damaging the normal smooth muscle cells. In their 
study rabbits were divided into four groups: the first, 
182 Hermans et al. 
July 1991 
American Heart Journal 
group was a control group, the second group had only 
a balloon dilatation of the aorta, the third group re- 
ceived the cytostatic agents (vincristine, 0.075 mg/kg, 
and actinomycin D, 0.015 mg/kg), and the fourth 
group underwent balloon dilatation and received cy- 
tostatic agents. All rabbits were killed 3 days later. 
Electron microscopic findings showed that the cyto- 
static agents prevented smooth muscle cell prolifer- 
ation without damaging the “normal” smooth muscle 
cells. The principle concern with these agents is the 
potential for serious side effects, because they are ca- 
pable of damaging other rapidly dividing cells, for 
example, those in the gastrointestinal tract, bone 
marrow, and reproductive system. Recently it has 
become possible to administer the drug locally with 
a specifically designed infusion catheter, which should 
limit systemic toxicity. 
Angiotensin-converting enzyme inhibitors. Severalor- 
gans contain local angiotensin-converting enzyme 
(ACE) systems. It appears that both the production 
of angiotensin II and its interaction with specific an- 
giotensin II receptors may take place in these tissues 
independent of the plasma renin-angiotensin 
system.67 ACE is a membrane-bound enzyme present 
in the walls of large arteries and veins. Angiotensin II 
receptors are present in the smooth muscle cells in 
the media of the vessel wall. In chronic hypertension 
it has been shown that long-term administration of 
an ACE inhibitor can reduce medial hypertrophy. It 
has been postulated that the local ACE system plays 
an important role in the remodeling process after ar- 
terial injury. There is also evidence to support the 
role of angiotensin II as a mitogen responsible for in- 
timal hyperplasia after PTCA. In rats, neointima 
formation was reduced by 80 % 14 days after balloon 
dilatation of the left carotid artery when an ACE in- 
hibitor was given either 6 days before, 1 hour before, 
or 2 days after angioplasty and continued until 14 
days after angioplasty. This effect seems to be dose 
dependent and is synergistic with the effect of hep- 
arin. There was no effect with administration of a 
single dose or when it was discontinued 2 days after 
balloon dilatation.67 Further study has shown that 
captopril (100 mg/kg/day) also reduced intimal hy- 
perplasia to almost the same extent. Two other 
vasodilators, verapamil and hydrazaline, demon- 
strated a lesser effect. 68 These results indicate that 
hemodynamic effects on the vascular walls may 
influence the formation of intimal hyperplasia after 
balloon catheterization and that ACE inhibitors may 
reduce intimal hyperplasia through additional mech- 
anisms related to inhibition of the angiotensin sys- 
tem. Currently a large multicenter randomized trial 
in Europe (Multicenter European Research Trial 
with Cilazapril After Angioplasty to Prevent Trans- 
luminal Coronary Obstruction and Restenosis) is 
underway to determine the effect of cilazapril on the 
incidence of restenosis. More than 700 patients have 
been randomly assigned to cilazapril or placebo 
starting 4 to 6 hours after PTCA, in addition to the 
standard therapy of 200 mg acetylsalicylic acid. Af- 
ter 6 months (or earlier if indicated by symptoms) 
follow-up angiography is performed. A similar trial 
with 1400 patients has recently begun in the United 
States, but with a different dosage schedule. 
Angiopeptin. It has been known for a long time that 
hypophysectomy inhibits neointimal plaque forma- 
tion in response to endothelial injury.6g This suggests 
that an endocrine factor may be involved in plaque 
formation. Recently the effect of a newly synthesized 
class of pituitary growth hormone-inhibiting agents 
on vascular smooth muscle cell hyperplasia after en- 
dothelial cell injury in vivo has been investigated. 
These compounds are peptide analogues of soma- 
tostatin and have a high affinity for somatostatin 
receptors on pituitary cells and inhibit release of pi- 
tuitary growth hormone. One of these agents, angio- 
peptin, was shown to inhibit vascular smooth muscle 
cell proliferation in response to a variety of vascular 
injuries. This seems to be due to a local effect directly 
on smooth muscle cells.70 This new group of agents is 
currently undergoing investigation as an inhibitor of 
several variants of “accelerated atherosclerosis” 
(postangioplasty, cardiac transplantation, and coro- 
nary bypass surgery). 
CALCIUM ANTAGONIST 
Coronary spasm is frequently seen during and 
shortly after PTCA and may have a role in the 
pathogenesis of restenosis71 Calcium antagonists by 
inhibiting vasospasm may reduce the incidence of 
restenosis in an animal mode1,72 and in two random- 
ized trials73t 74 calcium antagonists have not been 
shown to influence the incidence of restenosis. 
Diltiazem. In a study from the Montreal Heart 
Institute,73 92 patients received diltiazem (270 mg) 
for 3 months, and all underwent recatheterization 5 
to 10 months after balloon angioplasty or earlier if 
symptoms returned. All patients also received ace- 
tylsalicylic acid (650 mg) and dipyridamole (225 mg) 
for 6 months. Patients treated with diltiazem had a 
restenosis rate of 15 % versus 22 % in the patients not 
treated with diltiazem (restenosis was defined as 
stenosis of 70% or more at the time of the follow-up 
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angiography). The average decrease in diameter 
during follow-up was 4 % in the diltiazem group and 
7% in the control group. It was concluded that dilt- 
iazem had no effect on restenosis and that coronary 
spasm is not a major mechanism of restenosis. 
Nifedipine. In a g-month follow-up trial at Emory 
University in Atlanta,74 241 patients were randomly 
assigned to either nifedipine (40 mg/day) or placebo. 
All patients also received acetylsalicylic acid (325 
mg/day). Restenosis was defined as a loss of more 
than 50% of the gain achieved at the time of PTCA. 
In patients who were compliant and underwent fol- 
low-up angiography (84 patients in both groups) 
there was no difference in restenosis rates: 29 % in the 
nifedipine group and 33% in the placebo group. 
LIPID-LOWERING DRUGS 
Epidemiologic trials have shown that a diet rich in 
(n-3) polyunsaturated fatty acids (present in high 
concentrations in most salt water fish) may account 
for the low incidence of coronary disease in Eskimos. 
Animal research has shown that these polyunsatu- 
rated fatty acids inhibit atherosclerosis in general. 
This can be partly explained through a lowering of 
serum lipid levels and decreased aggregation of 
platelets by altering the balance between prostacy- 
clin and thromboxane. In the last few years several 
trials have studied the effects of n-3 fatty acids in the 
prevention of restenosis after PTCA. 
Slack et a1.75 showed that adding 2.4 gm of fish oil 
each day (rich in eicosapentaenoic acid) to the usual 
post-PTCA regimen of calcium channel blocker, ni- 
trates, acetylsalicylic acid, and dipyridamole could 
reduce the incidence of clinical restenosis in patients 
with single-vessel disease (33 % in the placebo group 
vs 16% in the group treated with fish oil). In 49 pa- 
tients with multivessel disease, no influence could be 
shown. Reis et a1.76 showed that supplementing the 
normal diet with 6.0 gm of fish oil daily starting just 
before PTCA until 6 months later had no influence on 
the restenosis rate in 186 patients in whom PTCA 
was successful. Angiographic restenosis (70% diam- 
eter stenosis at a site previously dilated to less than 
50% ) was present in 34% of the group taking fish oil 
and 23% of the control group. However, repeat 
angiography was performed in only 68 patients 
(37 % ); almost all patients had a recurrence of chest 
pain, which contributed to selection bias at follow-up 
angiography. Milner et al. 77 found that the addition 
of 4.5 gm of fish oil each day to a normal diet in 194 
patients had a positive influence on the clinical re- 
stenosis rate with 19% (16 of 84 patients) in the fish 
oil group versus 35% (35 of 99 patients) in the pla- 
cebo group having a recurrence of chest pain. How- 
ever, in the first week 11 of 95 patients stopped tak- 
ing the medication because of side effects. 
In Dallas78 82 patients were randomly assigned to 
acetylsalicylic acid and dipyridamole with and with- 
out 3200 mg (18 capsules) of eicosapentaenoic acid. 
Treatment was started 7 days before PTCA and was 
discontinued 6 months after PTCA. In all 82 patients 
a second angiogram (on average 3 to 4 months after 
PTCA) was obtained. Restenosis was defined as 50 % 
or more narrowing of the dilatation site at follow-up 
angiography. Restenosis was seen in 46 % in the pla- 
cebo group and 19% in the treatment group. This 
trial suggests that n-3 fatty acids may effectively re- 
duce restenosis in high-risk patients provided they 
comply with the treatment and are pretreated start- 
ing 7 days before PTCA. In Melbourne7g 108 patients 
were randomly assigned to 10 capsules of fish oil or 
placebo. Medication was started the day before 
angioplasty and continued until 4 months after 
angioplasty. All patients also received acetylsalicylic 
acid and verapamil. Restenosis was defined as loss of 
>50 % of the gain in luminal diameter at angioplasty 
(using caliper measurement). No difference in angio- 
graphically defined restanosis rates was observed: 
34% in the group treated with fish oil versus 33% in 
the placebo group. 
It is clear that a consensus cannot be reached. 
These conclusions are in part related to differences in 
the design of the individual studies. Although all 
studies were randomized, only in two studies were 
patients and investigators blinded to the n-3 supple- 
ment. Different dosages and formulations were used 
and patient compliance varied in the studies. There 
were also differences in the timing of initiation of 
therapy and variable methods (coronary angiogra- 
phy, stress test, or symptoms) for the detection of 
restenosis. 
Cholesterol-lowering drugs. Hypercholesterolemia 
is a well-known risk factor for ischemic heart disease. 
Lipid modification is an important goal in secondary 
prevention in halting the progression of atheroscle- 
rosis in general and possibly after angioplasty. Re- 
cently it was shown that lovastatin reduces intimal 
hyperplasia after balloon angioplasty in rabbits with 
hypercholesterolemia. 8o However, two trials with 
postangioplasty patients in which the effects of lipid 
lowering on the incidence of restenosis8” 82 after 
PTCA were tested yielded conflicting results. 
In the first trialE1 157 patients were randomly as- 
signed to lovastatin or placebo for an unstated period 
of time. Only 50% of the patients underwent follow- 
up angiography at an average of 4 months after 
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PTCA (50 patients in the lovastatin group and 29 
patients in the control group). Restenosis was de- 
fined as narrowing of 50% or more at follow-up an- 
giography. Restenosis was seen in 14 % of the sites in 
the lovastatin group and in 47 % in the placebo group, 
suggesting a beneficial effect of lovastatin in this se- 
lect group. In the second trial82 aggressive treatment 
was used in 55 consecutive patients to lower choles- 
terol levels, including diet, colestipol, and lovastatin, 
starting on the day of PTCA. After 2 weeks the cho- 
lesterol level was reduced by 50 % . To date 44 of the 
55 patients have been restudied with a restenosis rate 
of 34 % . There was no difference in cholesterol levels 
between patients with and without restenosis. 
INHIBITORS OF INFLAMMATION 
Corticosteroids. Corticosteroids have been sug- 
gested as a potential restenosis inhibitor.83 Hydro- 
cortisone can inhibit growth of vascular smooth 
muscle in culture.3g However, in a randomized trial in 
which patients received placebo or corticosteroids 
from 48 hours before to 5 days after PTCA, there was 
no difference in restenosis rates (33% in both 
groups). 84 The same results were achieved when ste- 
roids were given as treatment to 102 patients with 
restenosis after PTCA.85 In addition to acetylsali- 
cylic acid, dipyridamole, and a calcium antagonist, 
patients received 125 mg methylprednisolone intra- 
muscularly 1 day before the repeat PTCA and 240 mg 
prednisone for 1 week. Only the 54 patients undergo- 
ing follow-up angiography were analyzed. Restenosis 
was defined as >50% diameter narrowing at the site. 
Restenosis was found in 36% of the stenoses in the 
group treated with steroids compared with 40% in 
the group receiving standard treatment. 
In a recent multicenter trial in the United States,86 
850 patients were randomly assigned to methylpred- 
nisolone or placebo 2 to 24 hours before PTCA. In 
71% of the patients follow-up angiography was per- 
formed. There was no difference between the two 
groups in the incidence of restenosis (defined as 
>50% diameter stenosis): 43% in the group treated 
with methylprednisolone versus 43 % of the patients 
in the group given placebo. These trials showed that 
administration of corticosteroids has no influence on 
the incidence of restenosis. 
Nonsteroidal antiinflammatory drugs. Ibuprofen is 
known to decrease platelet-thrombus deposition in 
polytetra fluoroethylene (PTFE)* arterial grafts. In 
a study of normal porcine common carotid arteries 
pretreated with heparin, balloon angioplasty was 
performed and followed by a bolus (12.5 mg/kg) and 
infusion (75 to 100 kg/kg/min) of ibuprofen or pla- 
*Gore-Tex vascular graft, registered trademark of W.L. Gore & Associates, 
Inc.. Elkton, Md. 
cebo. Quantitative lllIn-labeled autologous platelet 
deposition at the site of angioplasty was significantly 
reduced by ibuprofen. 87 Whether this will affect the 
risk of late restenosis is not known. 
FUTUREDEVELOPMENTS 
Until now we have not found a drug that prevents 
restenosis in patients undergoing angioplasty. In the 
near future the results will be known of currently on- 
going multicenter trials with a new ACE-inhibitor 
(cilazapril), serotinin antagonist (ketanserin), hiru- 
din, low molecular weight heparin, angiopeptin and 
fish oil. Other promising drugs such as thrombin 
blockers, antagonists of smooth muscle cells, growth 
factor blockers, prostacyclin analogues, and mono- 
clonal antibodies against platelet membrane recep- 
tors (GP IIb/IIIa) and the von Willebrand factor will 
be tested in clinical trials and may bring us closer to 
the solution of the restenosis problem. 
CONCLUSION 
Despite 13 years of clinical experience and research 
in the field of restenosis after PTCA, there have been 
no major breakthroughs in pharmacologic interven- 
tions. Assessment of the value of drug trials that have 
been performed in the past is extremly difficult 
because of differences in selection of patients, meth- 
ods of analysis, and definition of restenosis. Recently 
our group has reviewed the influence of these three 
factors on the outcome and conclusion of restenosis 
studies.88 Although there is no scientific proof that 
the tested drugs are effective, many clinicians con- 
tinue prescribing them to “prevent restenosis.” 
Clinical and experimental research must continue 
to look for the elusive “magic bullet” that can prevent 
aggregation of thrombocytes, spasm, proliferation of 
smooth muscle cells, and atherosclerosis without any 
side effects and, if possible, in only one tablet! More- 
over, the cost of this potential drug solution must be 
less expensive than repeating PTCA in 30% of all 
patients. It is clear that this magic drug has not been 
found, and in the meantime we will continue (re)di- 
lating while we search for a pharmacologic or techni- 
cal solution to the problem of restenosis. 
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